Brief: Olix Pharmaceuticals Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Olx101a In Patients With Hypertrophic Scars
03/06/2022 13:07
June 3 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE
2 CLINICAL TRIAL OF OLX101A IN PATIENTS WITH HYPERTROPHIC SCARS
Source text for Eikon: ID:nBw5zW4HGa
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment